Lyra Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference


Watertown, Mass. – May 28, 2019 – Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, today announced that the company will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019, at 9:00 a.m. ET. Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will provide an overview of the company and a business update. The Jefferies 2019 Healthcare Conference will be taking place June 4-7 in New York City.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, offering an alternative to conventional treatments or surgeries. The company’s lead drug candidate, LYR-210, offers a novel approach for directing anti-inflammatory medicine deep into sinonasal tissues for up to six months of therapy. With proprietary expertise in drug development and materials science, Lyra is applying its transmucosal therapeutic system – comprised of drug administered through a polymeric matrix – with the goal of enabling therapeutic action at the site of inflammation in the sinonasal passages. Lyra Therapeutics is located in Watertown, Massachusetts. For more information, please visit www.lyratx.com.

# # #

Media Contact:

Kathryn Morris

Tel: 914-204-6412

[email protected]

Investor Contact:

Laurence Watts

Tel: 619-916-7620

[email protected]